<p>阿爾凱默斯公司 (NASDAQ:ALKS - 免費報告) - HC Wainwright 在 5 月 18 日週一向投資者發佈的報告中下調了對阿爾凱默斯 2026 財年的每股收益 (EPS) 預期。HC Wainwright 分析師 D. Tsao 現在預測該公司將發佈每股收益為（$0.44），低於之前預測的（$0.41）。HC Wainwright 對該股票的評級為 “中性”，目標價為$43.00。市場普遍預計阿爾凱默斯當前全年的每股收益為（$0.42）。</p>
<p>其他一些券商也對 ALKS 發表了看法。美國銀行在 4 月 9 日的研究報告中將阿爾凱默斯的目標價從$34.00 上調至$36.00，並給予該公司 “中性” 評級。加拿大皇家銀行在 2 月 26 日的研究報告中將阿爾凱默斯的目標價從$47.00 下調至$45.00，並對該公司給予 “跑贏大盤” 評級。瑞銀集團在 5 月 6 日的研究報告中將阿爾凱默斯的目標價從$42.00 上調至$48.00，並給予該公司 “買入” 評級。富國銀行在 5 月 6 日的研究報告中將阿爾凱默斯的目標價從$43.00 上調至$44.00，並給予該公司 “增持” 評級。最後，Wolfe Research 在 2 月 23 日的研究報告中開始覆蓋阿爾凱默斯，給予 “跑贏大盤” 評級和$45.00 的目標價。一位分析師對該股票給予強烈買入評級，十一位分析師給予買入評級，五位分析師給予持有評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為$45.40。</p>
<p><strong>獲取我們關於阿爾凱默斯的最新報告</strong></p>
<h2>阿爾凱默斯股價下跌 0.5%</h2>
<p>阿爾凱默斯股票在週三以$37.00 開盤。該公司的市值為$61.7 億，市盈率為 41.11，貝塔值為 0.31。該公司的 50 日移動平均價格為$32.83，200 日移動平均價格為$31.41。公司流動比率為 1.70，當前比率為 2.27，債務與股本比率為 0.85。阿爾凱默斯的 12 個月低點為$25.17，12 個月高點為$39.56。</p>
<p>阿爾凱默斯 (NASDAQ:ALKS - 獲取免費報告) 最近在 2 月 14 日發佈了季度財報。該公司報告季度每股收益為$0.29。該季度的營業收入為$3.8455 億。阿爾凱默斯的股本回報率為 9.26%，淨利潤率為 9.78%。</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者和對沖基金最近增加或減少了對該股票的持股。Sanctuary Advisors LLC 在第四季度將其在阿爾凱默斯的持股增加了 2.7%。Sanctuary Advisors LLC 目前擁有該公司 12,141 股股票，價值$340,000，在上個季度又增持了 315 股。PNC 金融服務集團在第四季度將其在阿爾凱默斯的持股增加了 3.5%。PNC 金融服務集團目前擁有該公司 10,326 股股票，價值$289,000，在上個季度又增持了 351 股。Orion Portfolio Solutions LLC 在第三季度將其在阿爾凱默斯的持股增加了 4.5%。Orion Portfolio Solutions LLC 目前擁有該公司 8,762 股股票，價值$263,000，在上個季度又增持了 376 股。Horizon Investments LLC 在第三季度將其在阿爾凱默斯的持股增加了 0.9%。Horizon Investments LLC 目前擁有該公司 43,002 股股票，價值$1,290,000，在上個季度又增持了 387 股。最後，AMG National Trust Bank 在第三季度將其在阿爾凱默斯的持股增加了 0.6%。AMG National Trust Bank 目前擁有該公司 60,175 股股票，價值$1,805,000，在上個季度又增持了 388 股。對沖基金和其他機構投資者持有該公司 95.21% 的股份。</p>
<h2>內部買賣</h2>
<p>在相關消息中，執行副總裁 Craig C. Hopkinson 於 5 月 1 日星期五出售了 9,000 股阿爾凱默斯股票。該股票以平均價格$33.40 出售，總價值為$300,600.00。交易完成後，該執行副總裁持有該公司 81,389 股股票，價值約為$2,718,392.60。這筆交易代表其持股減少了 9.96%。該交易已在 SEC 的法律文件中披露，可以通過此超鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，高級副總裁 Christian Todd Nichols 於 3 月 2 日星期一出售了 6,000 股阿爾凱默斯股票。該股票以平均價格$30.00 出售，總價值為$180,000.00。交易完成後，該高級副總裁持有該公司 109,769 股股票，價值約為$3,293,070。這代表其持股減少了 5.18%。該銷售的披露信息可在 SEC 文件中找到。在上個季度，內部人士出售了 39,102 股公司股票，價值$1,265,090。公司內部人士持有該公司 4.59% 的股份。</p>
<h2>關於阿爾凱默斯</h2>
<p>(獲取免費報告)</p>
<p>阿爾凱默斯公司是一家生物製藥公司，專注於開發創新藥物，以滿足中樞神經系統 (CNS) 的未滿足需求。該公司運用其專有的藥物遞送技術和治療專業知識，推進對成癮、精神分裂症、雙相 I 型障礙和抑鬱症的治療。阿爾凱默斯的產品組合包括多個商業產品和一系列旨在改善患者結果和支持長期疾病管理的研究性療法。</p>
<p>阿爾凱默斯的商業產品線包括多個已獲批准的產品。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票而非阿爾凱默斯</li>
<li>HIVE 利用權力進行 AI 轉型</li>
<li>深入分析 NVIDIA 最新的投資組合動態</li>
<li>Brady Corp 進行大規模 AI 驅動的突破</li>
<li>為什麼家得寶的拋售可能成為一個巨大的機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw"/></p>
<p><em>這條即時新聞提醒是由敍事科學技術和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將任何關於此故事的問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在阿爾凱默斯嗎？</h2>
<p>在你考慮阿爾凱默斯之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而阿爾凱默斯並不在名單上。</p>
<p>雖然阿爾凱默斯目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

阿爾凱默斯

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

<p>HC Wainwright 將 Alkermes plc 的 2026 財年每股收益預測從（$0.41）下調至（$0.44）。該公司維持 “中性” 評級，目標價為 $43.00。其他分析師的意見各不相同，摩根大通將其目標價上調至 $36.00，瑞銀集團則將其上調至 $48.00。Alkermes 的股票開盤價為 $37.00，市值為 61.7 億美元</p>

<p>Alkermes plc (NASDAQ:ALKS - Free Report) - HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Alkermes in a note issued to investors on Monday, May 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.44) for the year, down from their prior forecast of ($0.41). HC Wainwright has a &#34;Neutral&#34; rating and a $43.00 price objective on the stock. The consensus estimate for Alkermes' current full-year earnings is ($0.42) per share.</p>
<div class="lb-trans"><p>阿爾凱默斯公司 (NASDAQ:ALKS - 免費報告) - HC Wainwright 在 5 月 18 日週一向投資者發佈的報告中下調了對阿爾凱默斯 2026 財年的每股收益 (EPS) 預期。HC Wainwright 分析師 D. Tsao 現在預測該公司將發佈每股收益為（$0.44），低於之前預測的（$0.41）。HC Wainwright 對該股票的評級為 “中性”，目標價為$43.00。市場普遍預計阿爾凱默斯當前全年的每股收益為（$0.42）。</p>
</div><p>A number of other brokerages have also weighed in on ALKS. Bank of America raised their price objective on Alkermes from $34.00 to $36.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, April 9th. Royal Bank Of Canada cut their price objective on Alkermes from $47.00 to $45.00 and set an &#34;outperform&#34; rating for the company in a research report on Thursday, February 26th. UBS Group raised their price objective on Alkermes from $42.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, May 6th. Wells Fargo &amp; Company raised their price objective on Alkermes from $43.00 to $44.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, May 6th. Finally, Wolfe Research began coverage on Alkermes in a research report on Monday, February 23rd. They set an &#34;outperform&#34; rating and a $45.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $45.40.</p>
<div class="lb-trans"><p>其他一些券商也對 ALKS 發表了看法。美國銀行在 4 月 9 日的研究報告中將阿爾凱默斯的目標價從$34.00 上調至$36.00，並給予該公司 “中性” 評級。加拿大皇家銀行在 2 月 26 日的研究報告中將阿爾凱默斯的目標價從$47.00 下調至$45.00，並對該公司給予 “跑贏大盤” 評級。瑞銀集團在 5 月 6 日的研究報告中將阿爾凱默斯的目標價從$42.00 上調至$48.00，並給予該公司 “買入” 評級。富國銀行在 5 月 6 日的研究報告中將阿爾凱默斯的目標價從$43.00 上調至$44.00，並給予該公司 “增持” 評級。最後，Wolfe Research 在 2 月 23 日的研究報告中開始覆蓋阿爾凱默斯，給予 “跑贏大盤” 評級和$45.00 的目標價。一位分析師對該股票給予強烈買入評級，十一位分析師給予買入評級，五位分析師給予持有評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為$45.40。</p>
</div><p><strong>Get Our Latest Report on Alkermes</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於阿爾凱默斯的最新報告</strong></p>
</div><h2>Alkermes Trading Down 0.5%</h2>
<div class="lb-trans"><h2>阿爾凱默斯股價下跌 0.5%</h2>
</div><p>Shares of Alkermes stock opened at $37.00 on Wednesday. The firm has a market cap of $6.17 billion, a price-to-earnings ratio of 41.11 and a beta of 0.31. The business has a 50-day moving average price of $32.83 and a 200-day moving average price of $31.41. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.85. Alkermes has a twelve month low of $25.17 and a twelve month high of $39.56.</p>
<div class="lb-trans"><p>阿爾凱默斯股票在週三以$37.00 開盤。該公司的市值為$61.7 億，市盈率為 41.11，貝塔值為 0.31。該公司的 50 日移動平均價格為$32.83，200 日移動平均價格為$31.41。公司流動比率為 1.70，當前比率為 2.27，債務與股本比率為 0.85。阿爾凱默斯的 12 個月低點為$25.17，12 個月高點為$39.56。</p>
</div><p>Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported $0.29 EPS for the quarter. The business had revenue of $384.55 million for the quarter. Alkermes had a return on equity of 9.26% and a net margin of 9.78%.</p>
<div class="lb-trans"><p>阿爾凱默斯 (NASDAQ:ALKS - 獲取免費報告) 最近在 2 月 14 日發佈了季度財報。該公司報告季度每股收益為$0.29。該季度的營業收入為$3.8455 億。阿爾凱默斯的股本回報率為 9.26%，淨利潤率為 9.78%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC grew its position in Alkermes by 2.7% in the fourth quarter. Sanctuary Advisors LLC now owns 12,141 shares of the company's stock worth $340,000 after acquiring an additional 315 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Alkermes by 3.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,326 shares of the company's stock worth $289,000 after acquiring an additional 351 shares in the last quarter. Orion Porfolio Solutions LLC grew its position in Alkermes by 4.5% in the third quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company's stock worth $263,000 after acquiring an additional 376 shares in the last quarter. Horizon Investments LLC grew its position in Alkermes by 0.9% in the third quarter. Horizon Investments LLC now owns 43,002 shares of the company's stock worth $1,290,000 after acquiring an additional 387 shares in the last quarter. Finally, AMG National Trust Bank grew its position in Alkermes by 0.6% in the third quarter. AMG National Trust Bank now owns 60,175 shares of the company's stock worth $1,805,000 after acquiring an additional 388 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近增加或減少了對該股票的持股。Sanctuary Advisors LLC 在第四季度將其在阿爾凱默斯的持股增加了 2.7%。Sanctuary Advisors LLC 目前擁有該公司 12,141 股股票，價值$340,000，在上個季度又增持了 315 股。PNC 金融服務集團在第四季度將其在阿爾凱默斯的持股增加了 3.5%。PNC 金融服務集團目前擁有該公司 10,326 股股票，價值$289,000，在上個季度又增持了 351 股。Orion Portfolio Solutions LLC 在第三季度將其在阿爾凱默斯的持股增加了 4.5%。Orion Portfolio Solutions LLC 目前擁有該公司 8,762 股股票，價值$263,000，在上個季度又增持了 376 股。Horizon Investments LLC 在第三季度將其在阿爾凱默斯的持股增加了 0.9%。Horizon Investments LLC 目前擁有該公司 43,002 股股票，價值$1,290,000，在上個季度又增持了 387 股。最後，AMG National Trust Bank 在第三季度將其在阿爾凱默斯的持股增加了 0.6%。AMG National Trust Bank 目前擁有該公司 60,175 股股票，價值$1,805,000，在上個季度又增持了 388 股。對沖基金和其他機構投資者持有該公司 95.21% 的股份。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $33.40, for a total value of $300,600.00. Following the completion of the transaction, the executive vice president owned 81,389 shares in the company, valued at approximately $2,718,392.60. This trade represents a 9.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Todd Nichols sold 6,000 shares of Alkermes stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. Following the completion of the transaction, the senior vice president owned 109,769 shares of the company's stock, valued at approximately $3,293,070. This represents a 5.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 39,102 shares of company stock worth $1,265,090. Corporate insiders own 4.59% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Craig C. Hopkinson 於 5 月 1 日星期五出售了 9,000 股阿爾凱默斯股票。該股票以平均價格$33.40 出售，總價值為$300,600.00。交易完成後，該執行副總裁持有該公司 81,389 股股票，價值約為$2,718,392.60。這筆交易代表其持股減少了 9.96%。該交易已在 SEC 的法律文件中披露，可以通過此超鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，高級副總裁 Christian Todd Nichols 於 3 月 2 日星期一出售了 6,000 股阿爾凱默斯股票。該股票以平均價格$30.00 出售，總價值為$180,000.00。交易完成後，該高級副總裁持有該公司 109,769 股股票，價值約為$3,293,070。這代表其持股減少了 5.18%。該銷售的披露信息可在 SEC 文件中找到。在上個季度，內部人士出售了 39,102 股公司股票，價值$1,265,090。公司內部人士持有該公司 4.59% 的股份。</p>
</div><h2>About Alkermes</h2>
<div class="lb-trans"><h2>關於阿爾凱默斯</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.</p>
<div class="lb-trans"><p>阿爾凱默斯公司是一家生物製藥公司，專注於開發創新藥物，以滿足中樞神經系統 (CNS) 的未滿足需求。該公司運用其專有的藥物遞送技術和治療專業知識，推進對成癮、精神分裂症、雙相 I 型障礙和抑鬱症的治療。阿爾凱默斯的產品組合包括多個商業產品和一系列旨在改善患者結果和支持長期疾病管理的研究性療法。</p>
</div><p>Alkermes' commercial franchise features several approved products.</p>
<div class="lb-trans"><p>阿爾凱默斯的商業產品線包括多個已獲批准的產品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Alkermes</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票而非阿爾凱默斯</li>
<li>HIVE 利用權力進行 AI 轉型</li>
<li>深入分析 NVIDIA 最新的投資組合動態</li>
<li>Brady Corp 進行大規模 AI 驅動的突破</li>
<li>為什麼家得寶的拋售可能成為一個巨大的機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ALKS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這條即時新聞提醒是由敍事科學技術和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將任何關於此故事的問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Alkermes Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在阿爾凱默斯嗎？</h2>
</div><p>Before you consider Alkermes, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮阿爾凱默斯之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而阿爾凱默斯並不在名單上。</p>
</div><p>While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然阿爾凱默斯目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 下調了阿爾凱默斯 2026 財年的每股收益預測